MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$100,000K
Proceeds from exercise of
warrants and options
$29K
Net cash provided by
financing activities
$93,831K
Canceled cashflow
$6,198K
Net increase
(decrease) in cash, cash...
$70,509K
Canceled cashflow
$23,322K
Payment of issuance
costs for private...
$6,198K
Accounts payable and
accrued expenses
$3,464K
Stock-based compensation
expense
$2,566K
Accrued interest on
marketable securities
$103K
Noncash lease expense
$50K
Amortization (accretion) of
premium (discounts) on...
-$17K
Net cash used in
operating activities
-$23,290K
Net cash (used in)
provided by investing...
-$32K
Canceled cashflow
$6,200K
Non-operating income
$3,050K
Net loss
-$19,054K
Prepaid expenses and
other current assets
$10,219K
Purchases of property and
equipment
$32K
Canceled cashflow
$3,050K
Gain on change in fair
value of derivative...
$200K
Depreciation
-$154K
Total operating loss
$22,104K
Total research and
development expenses
$14,645K
General and
administrative expenses
$7,459K
Back
Back
Cash Flow
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)
source: myfinsight.com